ArticleBiomedical materials (Bristol, England)2015
Anisotropic silk biomaterials containing cardiac extracellular matrix for cardiac tissue engineering.
Article in Biomedical materials (Bristol, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 100 citations in OpenAlex.
- Mechanical and structural responses of silk fibroin scaffolds to MechanoCulture T6® bioreactor loading and enzymatic degradation.Journal of the mechanical behavior of biomedical materials · 2026Article
- Heart Scar-In-A-Dish: Tissue Culture Platform to Study Myocardial Injury and Mechanics In Vitro.Journal of biomechanical engineering · 2026Article
- Silk Fibroin Particle-Laden Sponges as a Multiphase Controlled Release Platform.Regenerative engineering and translational medicine · 2025Article
- 3D vector field-guided toolpathing for 3D bioprinting.Communications engineering · 2025Article
- Biophysical properties and antimicrobial efficacy of a novel Silk Sericin Mineral Trioxide Aggregate.Frontiers in dental medicine · 2025Article
- Exploring the functional properties ofMaterials today. Communications · 2025Article
- Engineered heart tissue: Design considerations and the state of the art.Biophysics reviews · 2024Review
- Recent advances in soluble decellularized extracellular matrix for heart tissue engineering and organ modeling.Journal of biomaterials applications · 2023Review
- Silk Fibroin Particles as Carriers in the Development of Hemoglobin-Based Oxygen Carriers.Advanced nanobiomed research · 2023Article
- Graphene Oxide-Coated Patterned Silk Fibroin Films Promote Cell Adhesion and Induce Cardiomyogenic Differentiation of Human Mesenchymal Stem Cells.Biomolecules · 2023Article
- A Review on the Applications of Natural Biodegradable Nano Polymers in Cardiac Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2023Review
- Silk Fibroin Particles as Carriers in the Development of All-Natural Hemoglobin-Based Oxygen Carriers (HBOCs).bioRxiv : the preprint server for biology · 2023Article
- Artificial Scaffolds in Cardiac Tissue Engineering.Life (Basel, Switzerland) · 2022Review
- An aorta ECM extracted hydrogel as a biomaterial in vascular tissue engineering application.Progress in biomaterials · 2022Article
- Mimicking Native Heart Tissue Physiology and Pathology in Silk Fibroin Constructs through a Perfusion-Based Dynamic Mechanical Stimulation Microdevice.Advanced healthcare materials · 2022Article
- Enhanced BMP-2-Mediated Bone Repair Using an Anisotropic Silk Fibroin Scaffold Coated with Bone-like Apatite.International journal of molecular sciences · 2021Article
- Cardiac mechanostructure: Using mechanics and anisotropy as inspiration for developing epicardial therapies in treating myocardial infarction.Bioactive materials · 2021Review
- Tunable Human Myocardium Derived Decellularized Extracellular Matrix for 3D Bioprinting and Cardiac Tissue Engineering.Gels (Basel, Switzerland) · 2021Article
- Recapitulating Cardiac Structure and Function In Vitro from Simple to Complex Engineering.Micromachines · 2021Review
- Unconventional Biomaterials for Cardiovascular Tissue Engineering.Current opinion in biomedical engineering · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Cardiac malformations and disease are the leading causes of death in the United States in live-born infants and adults, respectively. In both of these cases, a decrease in the number of functional cardiomyocytes often results in improper growth of heart tissue, wound healing complications, and poor tissue repair. The field of cardiac tissue engineering seeks to address these concerns by developing cardiac patches created from a variety of biomaterial scaffolds to be used in surgical repair of the heart. These scaffolds should be fully degradable biomaterial systems with tunable properties such that the materials can be altered to meet the needs of both in vitro culture (e.g. disease modeling) and in vivo application (e.g. cardiac patch). Current platforms do not utilize both structural anisotropy and proper cell-matrix contacts to promote functional cardiac phenotypes and thus there is still a need for critically sized scaffolds that mimic both the structural and adhesive properties of native tissue. To address this need, we have developed a silk-based scaffold platform containing cardiac tissue-derived extracellular matrix (cECM). These silk-cECM composite scaffolds have tunable architectures, degradation rates, and mechanical properties. Subcutaneous implantation in rats demonstrated that addition of the cECM to aligned silk scaffold led to 99% endogenous cell infiltration and promoted vascularization of a critically sized scaffold (10 × 5 × 2.5 mm) after 4 weeks in vivo. In vitro, silk-cECM scaffolds maintained the HL-1 atrial cardiomyocytes and human embryonic stem cell-derived cardiomyocytes and promoted a more functional phenotype in both cell types. This class of hybrid silk-cECM anisotropic scaffolds offers new opportunities for developing more physiologically relevant tissues for cardiac repair and disease modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.